| Authors: |
St-Laurent MP; University of British Columbia, Vancouver, BC, Canada., Singh P; Mayo Clinic Arizona, Phoenix, AZ, USA., McConkey DJ; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA., Lucia MS; University of Colorado, Denver, CO, USA., Koshkin VS; University of California San Francisco, Helen Diller Family Cancer Center, San Francisco, CA, USA., Stratton KL; University of Oklahoma, Oklahoma City, OK, USA., Bivalacqua TJ; University of Pennsylvania, Philadelphia, PA, USA., Kassouf W; McGill University Health Center, Montreal, QC, Canada., Porten SP; University of California San Francisco, Helen Diller Family Cancer Center, San Francisco, CA, USA., Bangs R; Bladder Cancer Advocacy Network, Pittsford, NY, USA., Plets M; SWOG Statistics and Data Management Center, Seattle, WA, USA., Thompson IM Jr; University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Meeks JJ; Northwestern University, Feinberg School of Medicine, Chicago, IL, USA., Caruso VM; Convergent Genomics, Research and Development, San Francisco, CA, USA., Ward CT; Convergent Genomics, Research and Development, San Francisco, CA, USA., Mazzarella BC; Convergent Genomics, Research and Development, San Francisco, CA, USA., Phillips KG; Convergent Genomics, Research and Development, San Francisco, CA, USA., Bicocca VT; Convergent Genomics, Research and Development, San Francisco, CA, USA., Levin TG; Convergent Genomics, Research and Development, San Francisco, CA, USA., Lerner SP; Baylor College of Medicine, Dan L Duncan Cancer Center, Houston, TX, USA., Black PC; University of British Columbia, Vancouver, BC, Canada. Electronic address: peter.black@ubc.ca. |
